A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Fibromyalgia
  • Focus Registrational; Therapeutic Use
  • Acronyms AFFIRM
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 23 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2016 Top-line results published in a Tonix Pharmaceuticals Holding Corp media release.
    • 06 Sep 2016 Primary endpoint (Average perceived pain) has not been met, according to a Tonix Pharmaceuticals Holding Corp media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top